Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi-Aventis 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Sanofi-Aventis 2Q

Pharmaceutical sales were up 7% to $9.4 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-Aventis 2Q

2Q Revenues: $10.4 billion (+11%)

2Q Earnings: $3.2 billion (+29%)

YTD Revenues: $20.4 billion (+7%)

YTD Earnings: $6.2 billion (+22%)

Comments: Pharmaceutical sales were up 7% to $9.4 billion. Lantus sales were up 26% to $1.1 billion. Lovenox sales were up 13% to $1.1 billion. Taxotere sales were $820 million (+11%). Plavix sales were up 5% to $989 million. Eloxatin sales were down 4% to $496 million. Sales in the U.S. and Europe were up 5%, and 20% in emerging markets. Human vaccine sales were down 1% to $1.0 billion. This includes $32.5 million of H5N1 vaccine sales in the U.S., compared to $192.5 million in 2Q08. Excluding H5N1 vaccine sales, 2Q sales were up 18%. *Earnings in the quarter and YTD reflect adjusted income and exclude selected items.

Sign up today for Contracting & Outsourcing 2009!
stagging_cp.rodpub.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters